Canada-based Aurora Cannabis Inc., an international and publicly traded cannabis company, announced this week the January 27 launch of the company’s first line of German-domestic medical cannabis products. Manufactured in Leuna, Germany, products from Aurora’s IndiMed brand will be the company’s first to use cannabis produced in Germany.
“Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since Germany’s move to decriminalize cannabis earlier this year. As one of three facilities licensed to cultivate in Germany, we are uniquely positioned to offer domestic product from our EU-GMP facility in Leuna, Germany, which operates within Aurora’s global manufacturing network. It is through our expertise in cultivation and deep commitment to science and innovation that we introduce IndiMed to the German patients.” — Michael Simon, Interim President of Aurora Europe, in a press release
IndiMed is not the first medical cannabis brand tied to an international, Canada-based firm to launch in Germany, however — last November, Aphria RX, a subsidiary of Tilray Brands, launched its first commercial medical cannabis products grown in a facility in Neumünster, Germany, MJBizDaily reported.
Meanwhile, Germany enacted last year the European Union’s most recent round of significant cannabis reforms, legalizing the use and possession of cannabis by adults aged 18 and older. Additionally, a poll last month found that 59% of German citizens support fully legalizing and regulating the plant.